Prescient Therapeutics - Extension of Share Purchase Plan

Key points

• Extended closing date for Share Purchase Plan (SPP) to 18 September 2026
• SPP offers new shares at $0.065 each, an 18.8% discount
• Eligible shareholders can apply for up to A$30,000 of new shares
• All eligible directors have participated in the SPP

Full summary

Prescient Therapeutics, a clinical-stage oncology company, announced an extension of the closing date for its Share Purchase Plan (SPP) from 15 September 2026 to 18 September 2026. The extension was made to accommodate shareholders who experienced delays in receiving the SPP documentation. Eligible shareholders can apply for up to A$30,000 of new fully paid ordinary shares at $0.065 each, representing an 18.8% discount to the volume weighted average price over the 10 trading days before the SPP was announced. The company noted that all eligible directors have participated in the SPP.